Compare LIDR & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIDR | CNTX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.0M | 132.3M |
| IPO Year | N/A | 2021 |
| Metric | LIDR | CNTX |
|---|---|---|
| Price | $1.85 | $2.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $6.00 | $6.00 |
| AVG Volume (30 Days) | 978.4K | ★ 2.4M |
| Earning Date | 02-19-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $182,000.00 | N/A |
| Revenue This Year | $9.07 | N/A |
| Revenue Next Year | $2,660.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.49 | $0.49 |
| 52 Week High | $6.44 | $2.45 |
| Indicator | LIDR | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.27 | 83.09 |
| Support Level | $1.91 | $1.39 |
| Resistance Level | $2.15 | $1.65 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 0.12 | 97.65 |
AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.